Navigation Links
$4.2 million grant helps plan, launch first Alzheimer's prevention trials
Date:3/20/2012

Washington University School of Medicine in St. Louis has received nearly $4.2 million from the Alzheimer's Association to accelerate the launch of the first clinical trials to prevent the symptoms of Alzheimer's disease.

The award is the largest research grant in the history of the 32-year-old association.

Randall Bateman, MD, principal investigator of the grant and director of the Dominantly Inherited Alzheimer's Network (DIAN) Therapeutic Trials Unit (TTU) at Washington University, will lead the trials, which will determine if the disease can be halted or delayed before problems in memory and other brain functions become apparent.

The research will be conducted through the Dominantly Inherited Alzheimer's Network, an international research partnership focused on understanding inherited forms of Alzheimer's. DIAN is headed by John C. Morris, MD, Harvey A. and Dorismae Hacker Friedman Professor of Neurology at Washington University School of Medicine. Bateman and Morris treat patients at Barnes-Jewish Hospital.

"We're grateful for the Alzheimer's Association's support for these trials and for the generous support it has given us throughout the long journey that has led to them," Morris says. "We've been working for years to find a way to treat Alzheimer's disease before patients develop dementia, and it's very exciting to be making plans to start the first of such trials later this year."

"This project has the potential to dramatically accelerate the pace of treatment and prevention strategies for Alzheimer's," said William Thies, PhD, the Alzheimer's Association's chief medical and scientific officer. "We are convinced that helping to rapidly launch the DIAN-Therapeutic Trials Unit will accelerate discovery of therapies that will change the course of the Alzheimer's disease process and delay or stop the disease."

Families enrolled in the DIAN study have inherited forms of Alzheimer's that cause dementia at a much earlier age than the more common sporadic forms of the disease. Scientists have identified mutations in three genes that cause inherited Alzheimer's. An individual who inherits one of these mutations typically develops symptoms of the disease at approximately the same young age as his or her parents.

Last July, DIAN researchers announced at the Alzheimer's Association International Conference that they could detect biological markers of presymptomatic disease in DIAN participants up to 20 years before the patients were expected to develop memory problems.

"We want to prevent damage and loss of brain cells by intervening early in the disease process even before outward symptoms are evident, because by then it may be too late," says Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor in Neurology and director of the DIAN Therapeutic Trials Unit, which will conduct the new trial.

With the advice of a newly formed consortium of 10 pharmaceutical companies, DIAN researchers under Bateman's leadership will select what they believe to be promising pharmaceuticals for the trials. They plan to give the drugs to family members who have an early-onset Alzheimer's gene and biological markers of disease but do not yet have symptoms of dementia. The goal will be to see if treatment can reduce the biological markers, potentially delaying or preventing the onset of symptoms.

"Experimental treatments have risks, so to treat patients before symptoms occur, we must be sure that we have a firm grasp on who will develop Alzheimer's dementia," says Morris, who also is director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center at Washington University. "If we can find a way to delay or prevent dementia in DIAN participants, that would be a tremendous success story and very helpful in our efforts to treat the much more common sporadic forms of the illness."

The pharmaceutical consortium advising DIAN researchers is comprised of the Janssen Alzheimer Immunotherapy Pfizer Alliance, Biogen Idec, Elan, Eli Lilly, Genentech, Hoffman La-Roche, Mithridion, Novartis, Pfizer and Sanofi-Aventis.

"The DIAN Pharma Consortium is an indicator of how important the DIAN trials are," Bateman says. "It's amazing that 10 pharmaceutical companies that are normally competitors have agreed to work together to help provide advice about DIAN trials design."

The DIAN Therapeutic Trials Unit has launched the DIAN expanded registry for interested patients, family members, doctors and researchers. For more information or to register for potential participation in the trials, go to http://www.DIANXR.org.


'/>"/>
Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Amway One by One Campaign for Children Reaches 7 Million Kids
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
5. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
6. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
10. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
11. America's Hidden Pandemic: 100 Million Suffer From Sleep Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly ... for a series of therapeutic sessions to help Los Angeles-area actors cope with ... their lives. The series, known as “Mindfulness for Actors and Artists,” has been ...
(Date:2/10/2016)... ... 2016 , ... LaserShip, a regional parcel carrier that services the eastern U.S., ... last Friday in order to aid in the Flint water crisis. In 2014, LaserShip ... located in Clio, only 15 miles away from Flint. , “We have deep roots ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... together to expand dental health services to the developmentally disabled in the Coachella ... Dental’s operations to a new facility at 71-949 Highway 111, Suite 100-B, in ...
(Date:2/10/2016)... ... 2016 , ... As part of its ongoing series of aquatic therapy related ... features a dynamic expert and thoughtful presentation to give attendees a better sense of ... events are free to attend, but registration is required. , Rehabilitation of ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
(Date:2/10/2016)... , February 10, 2016 A ... which will be held at Victoria Park Plaza in ... an informative seminar on technology and future advances for late ... led by Lorna Graham , associate director of project ... to keep up with new regulations and standards in late ...
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging ... Medicus Ltd. (ASX: PME), has announced that the American ... Florida (UF) have selected the Visage 7 Enterprise ... of the Emergent/Critical Care Imaging SIMulation (SIM). SIM ... Diagnostic Imaging Program (WIDI), a multi-faceted and fully-integrated ...
Breaking Medicine Technology: